Related Experiment Video
Updated: Mar 15, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
15.2K
Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction
1Community General Hospital Medical Center, Sterling, Illinois; University of Illinois School of Medicine, Peoria, Illinois; Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland.
The American Journal of Cardiology
|September 14, 2016
Summary
New lipid-lowering therapies, including PCSK9 inhibitors, help patients with hypercholesterolemia achieve lower low-density lipoprotein cholesterol (LDL-C) goals. These advanced treatments offer improved cardiovascular disease risk reduction when statins are insufficient.
Area of Science:
- Cardiology
- Metabolic Disorders
- Pharmacology
Background:
- Lowering serum low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular disease (CVD) risk.
- Statin monotherapy is insufficient for many hypercholesterolemia patients to reach LDL-C goals.
- Genetic lipid metabolism disorders inform novel lipid-lowering strategies.
Purpose of the Study:
- To review novel lipid-lowering strategies beyond statins.
- To discuss the efficacy of new agents like mipomersen, lomitapide, and PCSK9 inhibitors.
- To highlight the potential of achieving very low LDL-C concentrations for CVD risk reduction.
Main Methods:
- Review of clinical trials and meta-analyses on lipid-lowering therapies.
- Discussion of novel mechanisms targeting LDL-C receptor degradation and apoprotein synthesis.
- Focus on the clinical application of mipomersen, lomitapide, alirocumab, and evolocumab.
Main Results:
- Novel agents, including PCSK9 inhibitors, enable achievement of very low LDL-C levels (<40 mg/dl).
- These therapies are particularly effective for patients with homozygous familial hypercholesterolemia.
- Current research investigates the cardiovascular benefits and long-term safety of profound LDL-C reduction.
Conclusions:
- Advanced therapies offer new avenues for managing hypercholesterolemia and reducing cardiovascular risk.
- PCSK9 inhibitors represent a significant advancement, allowing unprecedented LDL-C lowering.
- Further research is crucial to confirm the long-term impact and safety of achieving extremely low LDL-C levels.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
01:26Atherosclerosis III: Management
558
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
558
01:29Pharmacogenomics: Identification of New Drug Targets
73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
01:26Coronary Artery Disease IV: Preventive Measures
794
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
794
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
580
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
580
01:29Cholesterol: Significance and Regulation
1.8K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
1.8K